First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

布鲁顿酪氨酸激酶 伊布替尼 慢性淋巴细胞白血病 套细胞淋巴瘤 医学 滤泡性淋巴瘤 华登氏巨球蛋白血症 肿瘤溶解综合征 中性粒细胞减少症 癌症研究 内科学 淋巴瘤 白血病 酪氨酸激酶 毒性 化疗 受体
作者
John F. Seymour,Chan Y. Cheah,Ricardo Parrondo,Meghan C. Thompson,Don A. Stevens,Masa Lasica,Michael Wang,Abhijeet Kumar,Judith Trotman,Maan Alwan,Wei Ding,Kunthel By,Bilal Tariq,Xiangmei Chen,Shannon Fabre,Jason C. Paik,Amit Agarwal,Constantine S. Tam
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4401-4401 被引量:64
标识
DOI:10.1182/blood-2023-180109
摘要

Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Disease that progresses on BTKis often has BTK mutations that lead to treatment (tx) resistance; novel BTK-targeting agents that overcome BTKi resistance are needed. BGB-16673 is a heterobifunctional small molecule that binds to BTK and E3 ligase, resulting in BTK degradation via ubiquitination. In preclinical models, BGB-16673 degraded wild-type (WT) BTK and known covalent and noncovalent BTKi-resistant mutant proteins, leading to tumor suppression. Methods: Pts with R/R CLL, WM, MCL, MZL, non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or Richter transformation (RT) were eligible for this open-label, first-in-human, phase 1 trial (BGB-16673-101; NCT05006716). Pts must have received ≥2 prior therapies (≥1 for RT) and have an ECOG performance status of 0-2 and adequate end-organ function. In the US and Australia, pts must have received a covalent BTKi (cBTKi) if approved for their disease. BGB-16673 was dosed daily by mouth in 28-day cycles. Escalation using a Bayesian optimal interval design with 6 dose levels (50-600 mg once daily) is planned. Primary objectives are to assess safety/tolerability and establish the maximum tolerated dose (MTD) and recommended phase 2 dose. Key secondary objectives are to assess pharmacokinetics, pharmacodynamics (PD), and preliminary antitumor activity. Safety was assessed according to CTCAE v5.0 (all pts) and iwCLL hematologic toxicity criteria (pts with CLL). Dose-limiting toxicities (DLTs) were assessed in the first 4 weeks. Response was assessed per Lugano criteria for all except CLL (iwCLL 2018 criteria) and WM (iwWM-6 criteria). Results: As of May 26, 2023, 26 pts (10 CLL, 4 MCL, 2 MZL, 4 WM, 4 FL, 1 DLBCL, 1 RT) were enrolled at 5 dose levels (50 mg, 4; 100 mg, 9; 200 mg, 9; 350 mg, 3; 500 mg, 1). Median age was 70.5 y (range, 25-83). Median number of prior therapies was 3.5 (range, 2-9), including cBTKis (n=21; 10 CLL, 4 WM, 4 MCL, 1 MZL, 1 RT, 1 DLBCL), BCL2 inhibitors (n=12; 9 CLL, 2 WM, 1 RT), and noncovalent BTKis (ncBTKis; n=4; 2 CLL, 1 WM, 1 FL). In CLL, del17p/ TP53 mutation (n=8) and unmutated IGHV (n=7) were frequent. Median follow-up was 3.5 mo (range, 0.2-13.9). MTD was not reached. Treatment-emergent AEs (TEAEs) were reported by 88.5% of pts (grade [gr] ≥3, 46.2%; serious, 38.5%). The most common TEAEs were contusion (30.8%; no gr ≥3), pyrexia (23.1%; no gr ≥3), neutropenia/neutrophil count decreased (23.1%; gr ≥3, 15.4%), and lipase increased (23.1%; gr ≥3, 3.8%; all transient and asymptomatic). No hypertension or atrial fibrillation was observed. One pt died from sepsis with possible disease progression. No discontinuations due to AEs occurred. Two pts had dose reductions due to TEAEs (gr 3 hematuria with urinary tract infection and recurrent urothelial carcinoma and gr 2 arthralgia). One DLT occurred in 1 pt at 200 mg (gr 3 maculopapular rash on day 27; after 5-day dose hold, assigned dose was recommenced with persistent gr 1 rash). BGB-16673 exposure increased in a dose-dependent manner. At steady state with doses ≥50 mg daily, BGB-16673 exposure exceeded the calculated half maximal degradation concentration for WT and cysteine 481-mutated BTK for the dosing interval. Preliminary PD data showed deep, sustained reductions in BTK protein levels in peripheral blood and tumor tissue, even at the lowest dose. Most CLL pts experienced lymphocytosis during the first 3 cycles of tx. Twenty of 26 pts (77%) remain on therapy (discontinuation: 4 progressive disease, 2 withdrawal). Of 18 response-evaluable pts, 12 (67%) responded (5/6 CLL, 1/3 MCL, 2/2 MZL, 3/4 WM, 1/2 FL, 0/1 DLBCL; 1 CR in MCL, all others had PR; Figure), including pts who received a cBTKi (n=10) and an ncBTKi (n=2). Responses started at the lowest dose level. All responders remain in response, the longest responder remaining on tx for 60 weeks. Conclusions: Preliminary data from this ongoing, first-in-human study of the novel BTK degrader BGB-16673 demonstrate a tolerable safety profile and clinical responses in heavily pretreated pts with B-cell malignancies, including those with BTKi-resistant disease. Substantial reductions in BTK protein levels in peripheral blood and tumor tissue were also observed, demonstrating proof-of-concept of a strong, on-target effect.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YTttt_发布了新的文献求助10
1秒前
许家星发布了新的文献求助100
1秒前
1秒前
缓慢冰兰完成签到,获得积分10
2秒前
yummy完成签到,获得积分10
2秒前
2秒前
汉堡包的应助被陈曦读研版采纳,获得10
3秒前
岁月静好发布了新的文献求助10
3秒前
Akim的应助被陈曦读研版采纳,获得10
3秒前
3秒前
星辰大海的应助被Clarissa采纳,获得10
4秒前
4秒前
sasa发布了新的文献求助10
5秒前
谷风习习完成签到,获得积分10
5秒前
5秒前
Zd完成签到,获得积分20
5秒前
科研通AI2S的应助被留不住的神采纳,获得10
6秒前
6秒前
胡歌完成签到,获得积分20
6秒前
搜集达人的应助被向蕊采纳,获得10
6秒前
顺心谷冬完成签到 ,获得积分10
6秒前
思源的应助被sjj采纳,获得10
7秒前
浩宁发布了新的文献求助10
8秒前
KH发布了新的文献求助10
9秒前
2024发布了新的文献求助10
9秒前
Yu完成签到,获得积分10
9秒前
bb糯发布了新的文献求助20
9秒前
9秒前
搞怪的老九的应助被唐飒采纳,获得10
10秒前
10秒前
Maestro_S的应助被关厚朴采纳,获得10
11秒前
11秒前
机智的白卉的应助被369ninja采纳,获得10
11秒前
酷波er的应助被Nuyoah采纳,获得10
12秒前
芒go发布了新的文献求助10
13秒前
一只小虾米完成签到,获得积分10
13秒前
14秒前
CipherSage的应助被失眠凡英采纳,获得10
14秒前
orange完成签到,获得积分10
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157304
求助须知:如何正确求助?哪些是违规求助? 9553290
关于积分的说明 21713683
捐赠科研通 7746409
什么是DOI,文献DOI怎么找? 3426733
关于科研通互助平台的介绍 2551498
邀请新用户注册赠送积分活动 2470679